RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Carlos Jiménez to Neuroblastoma

This is a "connection" page, showing publications Carlos Jiménez has written about Neuroblastoma.
Connection Strength

0.346
  1. Alvari?o R, Alfonso A, Pech-Puch D, Gegunde S, Rodr?guez J, Vieytes MR, Jim?nez C, Botana LM. Furanoditerpenes from Spongia (Spongia) tubulifera Display Mitochondrial-Mediated Neuroprotective Effects by Targeting Cyclophilin D. ACS Chem Neurosci. 2022 08 17; 13(16):2449-2463.
    View in: PubMed
    Score: 0.178
  2. Masanas M, Masi? N, Su?rez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jim?nez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guill?n G, Navarro A, Llobet-Navas D, Villanueva A, S?nchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura MF. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med. 2021 10; 11(10):e533.
    View in: PubMed
    Score: 0.168
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support